Key result
In hypertensive patients free of coronary artery disease, 4 weeks of nebivolol therapy significantly increased coronary flow reserve from 1.89 at baseline to 2.12 (P<0.0001).
Why the study?
Does nebivolol improve coronary flow reserve in newly diagnosed hypertensive patients without coronary heart disease?
Population
14 newly diagnosed, never-treated, World Health Organization grade I-II hypertensive patients, free of…
Comparison
Nebivolol 5 mg oral once daily for 4 weeks. vs Baseline.
Design
Cohort
Follow-up
4 weeks
Authors
Loading...
May improve coronary flow reserve in hypertension without CAD; hypothesis-generating and requires randomized confirmation before practice change.
Does nebivolol improve coronary flow reserve in newly diagnosed hypertensive patients without coronary heart disease?
Absolute Event Rate: 2.12% vs 1.89%
p-value: p=<0.0001
A 4-week treatment with nebivolol significantly improves coronary flow reserve in newly diagnosed hypertensive patients without coronary artery disease.
Galderisi et al. (2004) studied uncomplicated arterial hypertension (n=14). Nebivolol vs. Baseline was evaluated on coronary flow reserve (CFR) (p=<0.0001). In hypertensive patients free of coronary artery disease, 4 weeks of nebivolol therapy significantly increased coronary flow reserve from 1.89 at baseline to 2.12 (P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: